Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary-progressive multiple sclerosis.

David H Miller1, Siobhan M Leary

  • 1Department of Neuroinflammation, Institute of Neurology, University College London, London, UK. d.miller@ion.ucl.ac.uk

The Lancet. Neurology
|September 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.

Neurology·2025
Same author

Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.

Practical neurology·2024
Same author

What is rehabilitation?

Practical neurology·2024
Same author

Projection of Interspecific Competition (PIC) Matrices: A Conceptual Framework for Inclusion in Population Risk Assessments.

Environmental toxicology and chemistry·2024
Same author

AOP Report: Adverse Outcome Pathways for Aromatase Inhibition or Androgen Receptor Agonism Leading to Male-Biased Sex Ratio and Population Decline in Fish.

Environmental toxicology and chemistry·2023
Same author

Investigating Vernal Pool Fairy Shrimp Exposure to Organophosphate Pesticides: Implications for Population-Level Risk Assessment.

Ecologies·2022
Same journal

Correction to Lancet Neurol 2026; 25: 631.

The Lancet. Neurology·2026
Same journal

Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2025; 24: 740-52.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 357-67.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 451-68.

The Lancet. Neurology·2026
Same journal

Clinical presentations and pathophysiological mechanisms of dystroglycanopathy: advancing therapeutic strategies.

The Lancet. Neurology·2026
See all related articles

Primary-progressive multiple sclerosis (PPMS) involves gradual neurological decline, affecting older men more than women. Current treatments are ineffective, highlighting the need for new neuroprotective therapies.

Area of Science:

  • Neurology
  • Neuroimmunology
  • Neurodegeneration

Background:

  • Primary-progressive multiple sclerosis (PPMS) affects 10-15% of MS patients with gradual neurological disability.
  • PPMS onset is typically later in life and affects more men compared to relapse-onset MS.
  • Pathogenesis of PPMS, particularly immune-mediated mechanisms, remains unclear.

Purpose of the Study:

  • To summarize the characteristics of PPMS.
  • To discuss diagnostic methods for PPMS.
  • To identify areas for future research in PPMS.

Main Methods:

  • Review of clinical presentations and MRI findings in PPMS.
  • Examination of cerebrospinal fluid (CSF) for diagnostic markers.
  • Assessment of current treatment efficacy in PPMS.

Related Experiment Videos

Main Results:

  • PPMS is characterized by less evident inflammatory lesions but shows diffuse axonal loss and grey/white matter abnormalities.
  • Spinal cord atrophy correlates with progressive spastic paraplegia.
  • Conventional immunomodulatory therapies like interferon beta and glatiramer acetate are ineffective for PPMS.

Conclusions:

  • Neuroaxonal degeneration underlies PPMS, but its precise mechanisms require further elucidation.
  • MRI and CSF analysis are crucial for PPMS diagnosis.
  • Future research should prioritize understanding axonal loss mechanisms, improving clinical trial design, and developing neuroprotective treatments for PPMS.